Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B by �쟾�옱�쑄 et al.
Copyright © 2013 by The Korean Association for the Study of the Liver
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 2287-2728      
eISSN 2287-285X
http://dx.doi.org/10.3350/cmh.2013.19.1.29
Clinical and Molecular Hepatology 2013;19:29-35Original Article
INTRODUCTION 
Chronic hepatitis B (CHB) affects 400 million individuals world-
wide and is a leading cause of liver-related morbidity and mortal-
ity.1,2 Studies have demonstrated that the risk of liver disease pro-
gression in patients with CHB is associated with elevated hepatitis 
B virus (HBV) DNA levels.3 The introduction of oral nucleos(t)ides 
analogue (NA) therapy in the last two decades has revolutionized 
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the treatment of CHB. By achieving sustained virologic suppres-
sion, long-term NA therapy has been shown to reduce cirrhotic 
complications and the hepatocellular carcinoma (HCC).
Unfortunately, antiviral resistance remains an important issue 
in long-term treatment antiviral treatment. For lamivudine (LAM), 
the signature rtM204V/I and rtL180M mutations occur in more 
than 70% of CHB patients after five years of therapy.4,5 Under 
these circumstances, either switching to adefovir dipivoxil (ADV) 
monotherapy or adding ADV to LAM has proven to be effective 
in treating LAM-resistant CHB and there are no significant dif-
ferences between the two regimens in the suppression of viral 
replication during the first year of treatment.6 However, adding 
sequential LAM to ADV monotherapy leaves one vulnerable to 
developing ADV resistance and can result in the emergence of so-
called multidrug-resistant (MDR) HBV strains with resistant muta-
tions co-locating on the same viral genome.7
While the incidence of MDR HBV due to sequential LAM-ADV 
antiviral therapy is increasing worldwide, tenofovir-based rescue 
therapy has demonstrated favorable virologic outcomes.8,9 In ar-
eas where tenofovir is not yet available (e.g. Korea), such patients 
receive either entecavir (ETV) monotherapy, a combination of ETV 
and ADV, or a combination of LAM and ADV. However, relatively 
little is known about the efficacy of these rescue therapies in 
treating CHB that is resistant to both LAM and ADV.
In this study we compared the therapeutic efficacy of combina-
tion therapy with ETV and ADV to ETV monotherapy and combi-
nation therapy with LAM and ADV in CHB patients who demon-
strate both LAM and ADV resistance.
MATERIALS AND METHODS
Study population
From January 2005 to March 2012, 762 CHB patients were 
treated with ADV switch therapy or combination therapy with 
ADV and LAM due to the emergence of YMDD mutations during 
LAM treatment at Severance Hospital, Yonsei University College 
of Medicine in Seoul, Korea. Among them, 128 patients who also 
had an ADV mutation met the criteria for this study. All patients 
had been positive for hepatitis B surface antigen (HBsAg) for at 
least six months prior to antiviral treatment.10
The exclusion criteria were as follows: a history of hepatic de-
compression including presence of ascites, variceal bleeding, or 
hepatic encephalopathy at enrollment (n=16); a history of HCC 
at enrollment (n=14); concomitant liver disease other than CHB 
including autoimmune hepatitis, coinfection with hepatitis C and 
D virus or human immunodeficiency virus (HIV) (n=8); alcohol 
ingestion in excess of 40 g/day for more than five years (n=12); 
a history of liver transplantation (n=7); and follow-up period less 
than 12 months (n=23). 
The study was performed in accordance with the ethical guide-
lines of the 1975 Declaration of Helsinki and approved by the In-
stitutional Review Board of Severance Hospital, Yonsei University 
Health System. Prior to enrolling in this study, patients provided 
informed consent by agreeing to participate and signing an In-
formed Consent Form.
Patient follow-up and definitions of virologic 
parameters
All patients were seen at baseline and at 3, 6, 12, 18, and 24 
months, and routine blood chemistry tests, serum HBV DNA level, 
and serologic markers (HBeAg/anti-HBe in the case of HBeAg-
positive CHB) were assessed at all time points. HBsAg, HBeAg, 
and antibody to HBeAg (anti-HBe) were tested by enzyme-linked 
immunosorbent assay (ELISA; Abbott Laboratories, Chicago, IL, 
USA) and serum HBV DNA levels were quantified using a commer-
cially available real-time polymerase chain reaction (PCR) assay 
(COBAS AmpliPrep-COBAS TaqMan HBV test, Roche) with a linear 
detection range of 20-170,000,000 IU/mL. The serum alanine ami-
notransferase (ALT) level was measured using standard laboratory 
procedures with the upper limit of normal set at 46 IU/mL.
Primary non-response to antiviral therapy was defined as a <1 
log10 IU/mL reduction in HBV DNA concentration at three months. 
Virologic response was defined as an undetectable HBV DNA level 
(<20 IU/mL).11 Virologic breakthrough was defined as a confirmed 
increase in HBV DNA level of >1 log10 IU/mL from the nadir during 
antiviral therapy.12 A biochemical breakthrough was defined as 
an increase in ALT to greater than the upper limit of normal in ac-
cordance with virologic breakthrough after initial normalization.13 
Antiviral resistance to LAM or ADV was defined genotypically us-
ing restriction fragment mass polymorphism (RFMP), as previously 
described.14,15 
The primary objective of this study was to evaluate the virologic 
response to rescue regimens. The secondary goal was to evaluate 
the serologic and biochemical response, virologic breakthrough, 
and safety profiles of each regimen.
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Statistical analyses
Continuous variables were compared using a two-tailed Stu-
dent’s t-test (and if appropriate, Mann-Whitney test) or a one-way 
ANOVA method (and if appropriate, Kruskal-Wallis method). The 
repeated-measures ANOVA method was used to evaluate the dif-
ferences between mean HBV levels for each regimen. Categorical 
data were compared using the Chi-squared test or Fisher’s exact 
test. 
Statistical analyses were performed using SPSS software (ver. 
18.0; SAS Institute Inc., Cary, NC, USA). A value of P<0.05 was 
considered statistically significant.
RESULTS
Participant characteristics at baseline
A total of 48 patients were included in this study. Sixteen 
patients were treated with ETV monotherapy (1 mg/day; ETV 
monotherapy group), 20 patients were treated with a combination 
of LAM (100 mg/day) and ADV (10 mg/day) (LAM+ADV group), 
and 12 patients were treated with a combination of ETV (1 mg/
day) and ADV (10 mg/day) (ETV+ADV group) (Fig. 1). The charac-
teristics of each group are shown in Table 1. There were no sig-
nificant differences in characteristics between the three treatment 
groups, including age, gender, serum ALT, and HBeAg positivity 
rate. The median duration of antiviral treatment was also similar 
among the groups: 23.93 months in the ETV monotherapy group, 
19.30 months in the LAM+ADV group, and 18.37 months in the 
ETV+ADV group. Baseline serum HBV DNA levels were 6.08 (range 
2.09-8.04) log10 IU/mL, 4.92 (range 2.34-7.77) log10 IU/mL, and 
5.52 (range 2.54-8.23) log10 IU/mL, respectively (P=0.223).
Virologic, biochemical, and serologic responses
The virologic outcomes including virologic response, bio-
chemical response, and serologic response in the three treatment 
groups are illustrated in Table 2. Patients in the ETV+ADV group 
tended to demonstrate a higher virologic response at 24 months 
(40.0%) although the data failed to show statistical significance 
(P=0.656). Among patients who had high baseline ALT levels, the 
proportion of patients with ALT normalization did not significantly 
differ among the three groups (100.0%, 90.0%, and 100.0%, 
respectively). Among patients who were HBeAg-positive at base-
line, 16.7% of the ETV monotherapy group, 0% of the LAM+ADV 
group, and 9.1% of the ETV+ADV group achieved HBeAg loss. 
The mean reduction and mean changes in serum HBV DNA lev-
els over 24 months in the three groups are shown in Table 3 and 
Table 1. Patient characteristics at baseline
Characteristics ETV group (n = 16) LAM+ADV group (n = 20) ETV+ADV group (n = 12) P-value
Median follow-up, months (range)       23.9 (12.1-40.8)     19.3 (12.1-60.9)    18.4 (12.1-29.1) 0.234
Median age, years (range)     45 (23-60)   49 (23-67)   46 (25-72) 0.253
Males, n (%) 14 (87.5) 15 (75.0) 11 (91.7) 0.414
Median prior antiviral therapy duration, months (range)
  Lamivudine     15.5 (6.2-29.6)     15.0 (8.9-89.3) 17.1 (1.8-93.1) 0.123
  Adefovir        31.1 (20.6-64.8)       27.6 (12.8-65.8)   33.3 (12.2-60.9) 0.118
HBeAg positive (%) 12 (75.0) 17 (85.0) 11 (91.7) 0.494
Median ALT level, IU/mL (range)      52 (14-283)     29 (10-197)  73 (17-166) 0.400
Median HBV DNA level, log10 IU/mL (range)     6.1 (2.1-8.0)    4.9 (2.3-7.8) 5.5 (2.5-8.2) 0.223
Figure 1. Schematic diagram of the enrolled patients.
Chronic hepatitis B patients who had been treated with LAM, from January 
2005 to March 2012 at Yonsei university college of Medicine ; 1028
Patients who developed YMDD mutations ; 762
Patients who developedADV mutations afterADV addition or switch to ADV therapy ; 128
Patients with exclusion criteria ; 80
-Hepatic decompression 16
-Evidence of  HCC 14
-Current alcohol or substant use 12
-Serious concurrent medical condition 8
-Prior organ transplantation 7
-Follow up period <12months 23
LAM + ADV ; 20 ETV+ ADV ; 12ETV monotherapy; 16
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Figure 2. The decline of serum HBV DNA from baseline tended 
to be the greatest in the ETV+ADV group at all time points (12th 
month: -2.55, 24th month: -4.27 log10 IU/mL) although no statisti-
cal significance was found (all P>0.05).
Virologic breakthrough
All primary non-response and virologic breakthroughs are 
illustrated in Table 4. In total, 13 patients experienced virologic 
breakthroughs during the 24 months of treatment. Among them, 
six (37.5%) belonged to the ETV monotherapy group and six 
(30.0%) belonged to the LAM+ADV group, while only one patient 
(8.3%) was part of the ETV+ADV group. The rate of primary non-
response tended to be higher in the LAM+ADV and ETV+ADV 
groups than in the ETV monotherapy group, but the difference 
was not statistically significant (P =0.219). Among 6 patients 
with virologic breakthroughs who were previously managed with 
ETV monotherapy, 4 patients (66.7%) showed genotypic ETV 
resistance (two in rtS202 and two in rtT184) in conjunction with 
biochemical breakthrough.
DISCUSSION
ADV has shown to be efficacious and safe for up to five years 
in HBeAg-positive and HBeAg-negative CHB patients with LAM-
resistance. However, several studies have reported that ADV resis-
Table 2. Comparison of virologic responses, biochemical responses, and serologic responses in the three treatment groups*
Outcome ETV group LAM+ADV group ETV+ADV group P-value
Virologic response at
   3 months   5/16 (31.3)   5/16 (31.3) 1/12 (8.3) 0.322
   6 months   1/10 (10.0)   6/20 (30.0) 1/12 (8.3) 0.233
 12 months 0/16 (0.0)   6/18 (38.9)   2/11 (27.3) 0.070
 18 months   4/14 (28.6)   2/11 (27.3)    2/8 (37.5) 0.838
 24 months  2/10 (20.0)   2/10 (20.0)    2/5 (40.0) 0.656
ALT normalization      9/9 (100.0)   9/10 (90.0) 10/10 (100.0) 0.387
HBeAg loss 2/12 (16.7) 0/17 (0.0) 1/11 (9.1) 0.247
*Presented as n (%).
Table 3. Comparison of mean serum HBV DNA levels and mean reductions therein in the three treatment groups*
Outcome ETV group LAM+ADV group ETV+ADV group P-value
Mean serum HBV DNA level (log10 IU/mL) at 
   0 months 5.91±1.55 5.10±1.57 5.74±1.63 0.281 
   3 months 2.45±1.88 2.50±1.99 3.36±1.70 0.381 
   6 months 2.65±1.24 3.13±2.37 3.26±2.04 0.765 
 12 months 3.56±1.92 2.88±2.48 2.97±1.90 0.640 
 18 months 3.43±2.58 2.96±2.21 2.27±1.62 0.516 
 24 months 3.23±2.36 2.87±2.10 1.60±1.55 0.382
*Serum HBV DNA level presented as mean ± standard deviation.
Figure 2. Changes in serum HBV DNA levels from baseline during the 
treatment period in the ETV monotherapy group, and the LAM+ADV 
and ETV+ADV combination therapy groups.
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tance mutations frequently develop in LAM-resistant patients after 
switching to ADV monotherapy.14,16,17 Therefore, current interna-
tional guidelines recommend initiating combination therapy rather 
than switching to ADV monotherapy. In many countries within 
HBV endemic areas, including Korea, many patients have already 
received long-term LAM and ADV sequential monotherapy due to 
the relatively low cost and limited subsidization from the Korean 
health insurance system. Thus, investigations are needed to find 
an effective rescue therapy for patients who have experienced 
treatment failure with sequential LAM-ADV.
The best option for such patients is tenofovir-based combina-
tion therapy. Tenofovir, a new nucleotide analogue licensed in 
2008 for the treatment of HBV infection in Europe and the United 
States, is efficacious against wild-type and LAM-resistant HBV, 
both in vitro  and in vivo.18 A recent study showed that tenofovir 
had significant activity against HBV in patients with a high rate of 
genotypic resistance (rtM204I/V, rtA181T/V, and rtN236T muta-
tions), including in those patients who failed sequential LAM and 
ADV monotherapy.19 The American Association for the Study of 
the Liver Diseases (AASLD) practice guidelines from 2009 recom-
mend that a combination therapy of tenofovir and ETV be used 
in patients with sequential LAM and ADV treatment failure.11 
Likewise, the Asian Pacific Association for the Study of the Liver 
(APASL) guidelines from 2012 recommends a combination of ETV 
and tenofovir.20 Unfortunately, tenofovir is unavailable in many 
Asian countries. Therefore, we conducted this study by comparing 
the currently available antiviral agents in Asia to test the assump-
tion that combination ETV and ADV therapy may be a better, or at 
least comparable, option compared to ETV monotherapy or com-
bination LAM and ADV therapy.
In the present study, ETV+ADV combination therapy tended 
to more effectively suppress viral replication compared to either 
LAM+ADV combination therapy or ETV monotherapy in patients 
with both LAM and ADV resistance. Although there were no 
statistically significant differences, the ETV+ADV group showed 
a higher virologic response at 24 months, a greater reduction of 
mean serum HBV DNA levels at 12 and 24 months, and lower 
virologic and biochemical breakthroughs. Other recent studies 
have also shown that the addition of ADV is superior to switch-
ing to ETV monotherapy in LAM-resistant CHB.21,22 The long-
term efficacy of ETV monotherapy may be limited primarily due 
to frequent emergence of ETV resistance in ADV-refractory CHB 
patients with prior LAM resistance, while emergence of ETV resis-
tance in treatment-naïve patients is very rare.23 Accordingly, in our 
study, six patients (37.5%) in the ETV monotherapy group dem-
onstrated virologic breakthrough and among them, four patients 
had confirmed ETV resistance (two in rtS202 and two in rtT184). 
Furthermore, since CHB patients with sequential LAM and ADV re-
sistance often have resistant mutations to both drugs on the same 
viral genome,24 the combination of LAM and ADV demonstrated 
expectedly unsatisfactory antiviral efficacy. Indeed, recent stud-
ies have shown that combination therapy with LAM and ADV is 
ineffective and inferior even to ETV monotherapy.25 In this study, 
the ETV monotherapy group showed better results regarding the 
reduction of HBV DNA during the first six months of therapy com-
pared to the LAM+ADV group. However, after six months of treat-
ment, the ETV group was most prone to developing virologic and 
biochemical breakthrough. In the early period, ETV monotherapy 
had better efficacy than both the LAM+ADV or ETV+ADV groups 
due to suppression of ADV resistance, but the effect decreased as 
time passed with previous LAM resistance.
This study has some limitations. Firstly, since there was a rela-
tively small sample size, the superiority of ETV and ADV combina-
tion therapy was not clearly demonstrated despite the tendency 
toward better virologic outcomes (perhaps due to type II statistical 
error). Thus, physicians should exercise caution in interpreting 
these results, and further validations are required to resolve this 
issue. Secondly, since tenofovir is currently not available in Korea, 
we were unable to evaluate the efficacy of the tenofovir-based 
regimen. Further research is needed to evaluate more efficient 
combination therapies that include tenofovir. The combination 
therapy of ETV and ADV led to the virologic responses in 40% of 
subjects at most, thus further studies are needed with more po-
tent antiviral agents such as tenofovir.
In conclusion, for patients in Korea with both LAM and ADV 
MDR mutations, combination therapy with ETV and ADV tended 
Table 4. Comparison of rates of primary nonresponse, virologic breakthrough, and biochemical breakthrough in the three treatment groups*
Outcome ETV group LAM+ADV group ETV+ADV group P-value
Primary non-response 1/16 (6.3) 4/16 (25.0) 3/12 (25.0) 0.330 
Virologic breakthrough 6/16 (37.5) 6/20 (30.0) 1/12 (8.3) 0.219 
Biochemical breakthrough 4/16 (25.0) 2/20 (10.0) 0/12 (0.0) 0.133 
*Presented as n (%).
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to have a better virologic response compared to ETV monotherapy 
or combination therapy with LAM and ADV.
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